Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins.
The aim of the present work was to describe the effects of sibutramine on body weight and adiposity and to establish the potential involvement of neuropeptide Y (NPY) and orexins in the anorectic action of this drug. Male obese Zucker rats were daily administered with sibutramine (10 mg/kg, intraperitoneal) for two weeks. Carcass composition was assessed using the official methods of the Association of Official Analytical Chemists. Total body oxygen consumption was measured daily for 60 min before sibutramine or saline injection and for 30 min (from 60 to 90 min) after drug or saline injection. Hypothalamic arcuate and paraventricular nuclei, and the lateral hypothalamic area were immunostained for NPY, orexin A and orexin B. Commercial kits were used for serum determinations. Reductions in body weight and adipose tissue weights were observed after sibutramine treatment in obese Zucker rats. No changes in NPY immunostaining in the arcuate and paraventricular nuclei were found. Orexin A and orexin B immunostaining was not modified in the lateral hypothalamic area in treated rats. The reduction in body weight and adiposity induced by sibutramine was achieved by both a reduction in food intake and an increase in energy expenditure. NPY and orexins do not seem to be involved in the anorectic effect of sibutramine.
Casado
A
A
Department of Physiology, Faculty of Pharmacy, University of the Basque Country, Paseo de la Universidad 7, 01006 Vitoria, Spain.
Rodríguez
V M
VM
Portillo
M P
MP
Macarulla
M T
MT
Abecia
L C
LC
Echevarría
E
E
Casis
L
L
D000273:Adipose Tissue / Q000033:anatomy & histology; D000818:Animals; D001067:Appetite Depressants / Q000494:pharmacology* / Q000627:therapeutic use; D001823:Body Composition / Q000187:drug effects; D002352:Carrier Proteins / Q000032:analysis; D003503:Cyclobutanes / Q000494:pharmacology* / Q000627:therapeutic use; D004326:Drinking / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects*; D007031:Hypothalamus / Q000737:chemistry; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D009478:Neuropeptide Y / Q000032:analysis; D009479:Neuropeptides / Q000032:analysis; D009765:Obesity / Q000503:physiopathology*; D000068797:Orexins; D009929:Organ Size / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D051381:Rats; D011924:Rats, Zucker; D015430:Weight Gain / Q000187:drug effects*
D001067:Appetite Depressants; D002352:Carrier Proteins; D003503:Cyclobutanes; D047908:Intracellular Signaling Peptides and Proteins; D009478:Neuropeptide Y; D009479:Neuropeptides; D000068797:Orexins; C058254:sibutramine